Patterns of use and safety of ibrutinib inreal-life practice in onco-hematology
| dc.rights.license | open | en_US |
| dc.contributor.author | ALLOUCHERY, M. | |
| dc.contributor.author | PERAULT-POCHAT, M. C. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SALVO, Francesco | |
| dc.date.accessioned | 2024-10-09T11:57:26Z | |
| dc.date.available | 2024-10-09T11:57:26Z | |
| dc.date.issued | 2024-06-01 | |
| dc.identifier.issn | 0767-3981 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/202344 | |
| dc.description.abstractEn | Despite being a standard of care in B-cell malignancies, a benefit–risk assessment in real-life set- tings of ibrutinib, the first-in-class Bruton tyrosine kinase (BTK) inhibitor, was still needed. This work aimed to provide real-life data on patterns of use and safety of ibrutinib through two data sources, VigiBase® and SNDS. Firstly, co-administration of ibrutinib and anticoagulants was associated with a 2.5-fold increased risk of clinically relevant bleeding, without any difference between vitamin K antagonists and direct oral anticoagulants. Secondly, 1-year incidence of fungal invasive infections was 1.3% in ibrutinib- treated patients, with the following predictive factors: stem cell transplantation, neutropenia, corticosteroids, and chronic respiratory diseases, previous treatment and combination with anti-CD20 agents. Lastly, rele- vant safety signals emerged from VigiBase®, mainly cardiovascular and ocular reactions. Taken together, these findings contributed to providing essential information about monitoring and management of ibrutinib-treated patients and crucial insights for real- world surveillance of next-generation BTK inhibitors | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Ibrutinib | |
| dc.subject.en | Pharmacoepidemiology | |
| dc.subject.en | Pharma-Covigilance | |
| dc.subject.en | Targeted Therapy | |
| dc.title.en | Patterns of use and safety of ibrutinib inreal-life practice in onco-hematology | |
| dc.title.alternative | Fund Clin Pharmacol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/fcp.13014 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| bordeaux.journal | Fundamental & Clinical Pharmacology | en_US |
| bordeaux.page | 43-44 | en_US |
| bordeaux.volume | 38 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | S1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04728081 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-10-09T11:57:29Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Fundamental%20&%20Clinical%20Pharmacology&rft.date=2024-06-01&rft.volume=38&rft.issue=S1&rft.spage=43-44&rft.epage=43-44&rft.eissn=0767-3981&rft.issn=0767-3981&rft.au=ALLOUCHERY,%20M.&PERAULT-POCHAT,%20M.%20C.&SALVO,%20Francesco&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||